IP Verse

Methods Of Treating Hepatic Encephalopathy - EP2350096

The patent EP2350096 was granted to Salix Pharmaceuticals on Dec 11, 2019. The application was originally filed on Oct 2, 2009 under application number EP09818544A. The patent is currently recorded with a legal status of "Revoked".

EP2350096

SALIX PHARMACEUTICALS
Application Number
EP09818544A
Filing Date
Oct 2, 2009
Status
Revoked
May 29, 2025
Grant Date
Dec 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERSep 11, 2020HAMM & WITTKOPPADMISSIBLE
HOLLATZSep 11, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
STADA ARZNEIMITTELSep 11, 2020HAMM & WITTKOPPADMISSIBLE
ACCORD HEALTHCARESep 9, 2020BRAND MURRAY FULLERADMISSIBLE
TEVA PHARMACEUTICALSSep 9, 2020D YOUNGADMISSIBLE
AERASep 7, 2020AERAADMISSIBLE
AERASep 7, 2020BARDEHLE PAGENBERG SLADMISSIBLE
KRAUS & LEDERER PARTGMBBAug 31, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
CMS CAMERON MCKENNA NABARRO OLSWANGAug 6, 2020CMS CAMERON MCKENNA NABARRO OLSWANGADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP20050004635-
DESCRIPTIONUS20070873841-
DESCRIPTIONUS20080031329-
DESCRIPTIONUS20100658702-
DESCRIPTIONEP0161534
DESCRIPTIONIT1154655
DESCRIPTIONUS7045620
INTERNATIONAL-SEARCH-REPORTUS2004157840
INTERNATIONAL-SEARCH-REPORTUS2006210592
INTERNATIONAL-SEARCH-REPORTUS6562629
OPPOSITIONEP2498762
OPPOSITIONEP2512453
OPPOSITIONEP2608792
OPPOSITIONEP2785349
OPPOSITIONEP3302565
OPPOSITIONWO2009108814
SEARCHWO2009108814

Non-Patent Literature (NPL) Citations (52) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- R WILLIAMS ET AL, "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.", EUR J GASTROENTEROL HEPATOL, (20000201), vol. 12, no. 2, pages 203 - 208, XP055408536
OPPOSITION- "A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy", History of Changes for Study: NCT00298038, (20060228), URL: https://clinicaltrials.gov/ct2/history/NCT00298038?V_1=View#StudyPageTop, XP055767697-
OPPOSITION- Anonymous, "A 6-month Efficacy, Safety and Tolerability Study of Rifaximin in Preventing Hepatic Encephalopathy", Clinical trial NCT00298038, (20060228), pages 1 - 9, Clinical trial NCT00298038, (20200923), XP055733367-
OPPOSITION- Anonymous, "A 6-month Efficacy, Safety and Tolerability Study of Rifaximin in Preventing Hepatic Encephalopathy", Clinical trial NCT00298038, (20060228), pages 1 - 9, XP055733367-
OPPOSITION- Anonymous, "A 6-month Efficacy, Safety and Tolerability Study of Rifaximin in Preventing Hepatic Encephalopathy", CLINICAL TRIAL NCT00298038, (20080228), URL: https://www.clinicaltrials.gov/ct2/show/NCT00298038, XP055733367-
OPPOSITION- Anonymous, "History of Changes for Study: NCT00298038. A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy", Clinical Trial Study NCT00298038, (20060228), XP055767697-
OPPOSITION- anonymous, "History of Changes for Study: NCT00364689 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial", Clinical Trial Study NCT00364689, (20060815), URL: https://clinicaltrials.gov/ct2/history/NCT00364689?V_1=View#StudyPageTop, XP055770763-
OPPOSITION- B. SHEN et al., "Rifaximin for maintenance therapy in antiobiotic-dependent pouchitis", BMC Gastroenterology, (20080000), vol. 8, page 26, XP021034099-
OPPOSITION- Carolyn J. Logan, "2007 Annual Report and Form 10-K", Salix Pharmaceuticals, Inc., (20070000), pages i, 1 - F-29, XP055735955-
OPPOSITION- C SAMA et al., "Clinical Effects of Rifaximin in Patients with Hepatic Encephalopathy Intolerant or Nonresponsive to Previous Lactulose Treatment: An Open-Label, Pilot Study, page 415 discloses administering 3 x 400 mg of rifaximin daily", Current Therapeutic Research, (20040900), vol. 65, no. 5, pages 413 - 422, XP055733363-
OPPOSITION- D. FESTI et al., "Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy", Digestion, (20060200), vol. 73, no. suppl 1, pages 94 - 101, XP055771240-
OPPOSITION- F. POORDAD et al., "THE PROTECTIVE EFFECT OF RIFAXIMIN (1100 MG DAILY) FROM. HEPATIC ENCEPHALOPATHY OBSERVED IN A DOUBLE-BUND PLACEBO CONTROLLED STUDY ISSUBSTANTIATED AND DURABLE OVER THE LONG", Hepatology, (20090000), vol. 50, no. Suppl. 4, pages 448A - 449A, XP055770758-
OPPOSITION- Index of Hepatology, (20090000), vol. 50, no. Suppl. 4-
OPPOSITION- J. A. ADACHI et al., "Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders", Clinical Infectious Diseases, (20060000), vol. 42, pages 541 - 547, XP008103995-
OPPOSITION- Jiang Z D, Et Al, "Rifaximin: In vitro and in vivo Antibacterial Activity - A Review", Chemotherapy, (20050101), vol. 51, pages 67 - 72, XP055816074-
OPPOSITION- "List of Issues", J. Hepatol-
OPPOSITION- Loguercio Carmelina, Et Al, "Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study", Minerva Gastroenterologica e Dietologica, (20040301), pages 53 - 62, Minerva Gastroenterologica e Dietologica, (20210621), XP055816069-
OPPOSITION- RACHEL TAVARES DE MELO et al., "Rifaximin for the Treatment of Hepatic Encephalopathy", American Journal of Health-System Pharmacy, (20080500), vol. 65, pages 818 - 822, XP055767702-
OPPOSITION- Rachel Tavares De Melo, Lisa Charneski And Olga Hilas, "Rifaximin for the Treatment of Hepatic Encephalopathy", Am J Health-Syst Pharm, (20080501), vol. 65, pages 818 - 822, XP055767702-
OPPOSITION- R WILLIAMS et al., "''Rifaximin, a Nonabsorbed Oral Antibiotic, in the Treatment of Hepatic Encephalopathy: Antimicrobial Activity, Efficacy, and Safety", Antibiotics for Hepatic Encephalopathy, (20050000), vol. 5, no. 1, pages S10 - S18, XP055733789-
OPPOSITION- SALIX PHARMACEUTICALS et al., Xifaxan Prescribing Information, (20080301), XP008139843-
OPPOSITION- TAVARES DE MELO et al., "Rifaximin for the Treatment of Hepatic Encephalopathy", American Journal of Health-System Pharmacy, (20080501), vol. 65, pages 818 - 822, XP055767702-
OPPOSITION- Elliot B Tapper , Neehar D Parikh , Neil Sengupta , Jessica Mellinger, David Ratz , Anna S-F Lok , Grace L Su, "A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients With Cirrhosis", Hepatology, (20180000), vol. 68, no. 4, pages 1498 - 1507, XP055733333
OPPOSITION- CARROLL B. LEEVY et al., "Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy", Digestive Diseases and Sciences, (20070000), vol. 52, pages 737 - 741, XP019479057
OPPOSITION- Carroll B. Leevy ; James A. Phillips, "Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy", Digestive Diseases and Sciences, Kluwer Academic Publishers-Plenum Publishers, Ne, Ne, (20070124), vol. 52, no. 3, doi:10.1007/s10620-006-9442-4, ISSN 1573-2568, pages 737 - 741, XP019479057
OPPOSITION- C. B. LEEVY et al., "Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy", Dig Dis Sci, (20070000), vol. 52, pages 732 - 741, XP002669396
OPPOSITION- C. B. LEEVY et al., "Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy", Dig Dis Sci, (20070000), vol. 52, pages 737 - 741, XP002669396
OPPOSITION- S.J. MUNOZ, "Hepatic encephalopathy", Medical clinics of North America, (20080618), vol. 92, no. 4, pages 795 - 812, XP008116796
OPPOSITION- G. NEFF et al., "Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy", TRANSPLANTATION PROCEEDINGS, (20061215), vol. 38, no. 10, pages 3552 - 3555, XP005804096
OPPOSITION- Bass, N. et al, "93 RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL", Journal of Hepatology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (20090401), vol. 50, doi:10.1016/S0168-8278(09)60095-7, ISSN 0168-8278, page S39, XP026495706
OPPOSITION- N. BASS et al., "93 RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL", J. Hepatol., (20090425), vol. 50, no. Suppl. 1, page S39, XP026117729
OPPOSITION- N. BASS et al., "Rifaximin Is Effective In Maintaining Remission In Hepatic Encephalopathy: Results Of A Large, Randomized, Placebo-Controlled Trial", Abstracts Of The International Liver Congress TM 2009 , 44th Annual Meeting Of The European Association For The Study Of The Liver, Copenhagen, Denmark, (20090422), page S39, (20090515), XP026495706
OPPOSITION- Bass, Nathan M., "Emerging therapies for the management of hepatic encephalopathy", Seminars in liver disease, Thieme Medical Publishers, US, US, (20070801), vol. 27, no. suppl. 2, doi:10.1055/s-2007-984575, ISSN 0272-8087, pages 18 - 25, XP008148563
OPPOSITION- BASS N. M. et al., "Rifaximin Treatment in Hepatic Encephalopathy", New England Journal of Medicine, (20100325), vol. 362, no. 12, pages 1071 - 1081, XP055616660
OPPOSITION- Nathan M. Bass, Kevin D. Mullen, Et Al., "Rifaximin Treatment in Hepatic Encephalopathy", The New England Journal of Medicine, (20100325), vol. 362, no. 12, doi:10.1056/NEJMoa0907893, pages 1071 - 1081, XP055616660
OPPOSITION- N. M. BASS et al., "Rifaximin Treatment in Hepatic Encephalopathy", New England Journal of Medicine, (20100000), vol. 362, doi:10.1056/NEJMoa0907893, pages 1071 - 1081, XP055616660
OPPOSITION- BASS N M, "Review article: the current pharmacological therapies for hepatic encephalopathy.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE., GB, GB, (20070201), vol. 25, no. SUPPL 1, doi:10.1111/J.1746-6342.2006.03218.X, ISSN 0269-2813, pages 23 - 31, XP002669397
OPPOSITION- BASS N. M., "The current pharmacological therapies for hepatic encephalopathy", Aliment Pharmacol Ther, (20070000), vol. 25, no. 1, pages 23 - 31, XP002669397
OPPOSITION- N. M. BASS, "Review Article: The current pharmacological therapies for hepatic encephalopathy", Aliment Pharmacol Ther, (20060000), vol. 25, no. 1, pages 23 - 31, XP002669397
OPPOSITION- N. M. BASS, "Review article: the current pharmacological therapies for hepatic encephalopathy", Aliment Pharmacol Ther, (20060201), vol. 25, no. Suppl. 1, pages 23 - 31, XP002669397
OPPOSITION- C. SCARPIGNATO et al., "Rifaximin, a poorly absorbed antibiotic: Pharmacology and Clinical Potential", Chemotherapy, (20050000), vol. 51, no. 1, pages 36 - 68, XP009107325
OPPOSITION- Zeneroli, Maria Luisa; Avallone, Rossella; Corsi, Lorenzo; Venturini, Ivo; Baraldi, Claudia; Baraldi, Mario, "Management of Hepatic Encephalopathy: Role of Rifaximin", Chemotherapy, S. Karger AG, CH, CH, (20050401), vol. 51, no. suppl. 1, doi:10.1159/000081994, ISSN 0009-3157, pages 90 - 95, XP008148562
OPPOSITION- A. PUXEDDU et al., "Rifaximin in the treatment of chronic hepatic encephalopathy", Current Medical Research and Opinion, (19950000), vol. 13, no. 5, pages 274 - 281, XP055733786
OPPOSITION- A. PUXEDDU et al., "Rifaximin in the Treatment of Chronic Hepatic Encephalopathy", Current Medical Research and Opinion, (19950000), vol. 13, no. 5, pages 274 - 281, XP055733786
OPPOSITION- A. Puxeddu, M. Quartini, A. Massimetti, "Rifaximin in the treatment of chronic hepatic encephalopathy", Current Medical Research and Opinion, (19950101), vol. 13, doi:10.1185/03007999509111552, pages 274 - 281, XP055733786
OPPOSITION- Lawrence Kenneth R; Klee Jacqueline A, "Rifaximin for the treatment of hepatic encephalopathy", Pharmacotherapy, (20080000), vol. 28, no. 8, pages 1019 - 1032, XP008148564
OPPOSITION- Y PAIK et al., "Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomised Study Y", Yonsei Medical Journal, (20050000), vol. 46, no. 3, doi:10.3349/ymj.2005.46.3.399, pages 399 - 407, XP008139597
SEARCH- SALIX PHARMACEUTICALS ET AL, "Xifaxan Prescribing Information", (20080301), pages 1 - 2, 20080301, URL: http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf, (20110405), XP008139843 [X] 1-13,16-19 * the whole document * [I] 15-
SEARCH- LEEVY CARROLL B ET AL, "Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.", DIGESTIVE DISEASES AND SCIENCES MAR 2007 LNKD- PUBMED:17245628, (200703), vol. 52, no. 3, ISSN 0163-2116, pages 737 - 741, XP002669396 [X] 1-14,16,19 * abstract * * page 739 - page 741 *
SEARCH- BASS ET AL, "Emerging therapies for the management of hepatic encephalopathy", SEMINARS IN LIVER DISEASE, THIEME MEDICAL PUBLISHERS, US, (20070801), vol. 27, no. suppl. 2, doi:10.1055/S-2007-984575, ISSN 0272-8087, pages 18 - 25, XP008148563 [X] 1-14,16,19 * page 20, column left, paragraph 2nd * * page 23, column left, paragraph 1st *
SEARCH- BASS N M, "Review article: the current pharmacological therapies for hepatic encephalopathy.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS FEB 2007 LNKD- PUBMED:17295849, (200702), vol. 25 Suppl 1, ISSN 0269-2813, pages 23 - 31, XP002669397 [X] 1-13,16,19 * page 25, column right, paragraph 4th * * page 25, column left, paragraph 3rd * * page 27, column left, paragraph 3rd *
SEARCH- ZENEROLI MARIA LUISA ET AL, "Management of Hepatic Encephalopathy: Role of Rifaximin", CHEMOTHERAPY, S. KARGER AG, CH, (20050401), vol. 51, no. suppl. 1, doi:10.1159/000081994, ISSN 0009-3157, pages 90 - 95, XP008148562 [X] 1-13,16,19 * abstract * * page 93; table 1 * * pages 92,93 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents